Tetra Discovery Partners announced on 10/11/18 that the U.S. Patent and Trademark Office has issued a third patent covering the company’s selective phosphodiesterase-4D (PDE4D) inhibitor, BPN 14770, and related compounds. The new patent, US 10,093,686, covers claims for the use such compounds in the treatment of mild cognitive impairment, Parkinson’s disease, stroke and ischemia.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,